# OnCo record cstone (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/cstone/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "cstone" ;
  schema:name "CStone Pharmaceuticals"@en ;
  schema:alternateName "基石药业"@en, "CStone"@en, "cstone-pharmaceuticals"@en ;
  schema:description "CStone developed sugemalimab, the first Chinese PD-L1 antibody approved in Europe, and brought pralsetinib, avapritinib and ivosidenib to China."@en ;
  schema:url <https://onco.cc/companies/cstone/>, <https://www.cstonepharma.com/en/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://www.cstonepharma.com/en/> ;
  onco:tag "china" ;
  schema:addressCountry "CN" ;
  onco:sections <https://onco.cc/fronts/immunotherapy/>, <https://onco.cc/fronts/targeted-therapy/> ;
  onco:drugs <https://onco.cc/drugs/sugemalimab/>, <https://onco.cc/drugs/pralsetinib/>, <https://onco.cc/drugs/avapritinib/>, <https://onco.cc/drugs/ivosidenib/> ;
  onco:trials <https://onco.cc/trials/gemstone-302/>, <https://onco.cc/trials/nct04194775/>, <https://onco.cc/trials/nct05297890/>, <https://onco.cc/trials/nct06741644/> .